CTIS2023-508860-31-00进行中（未招募）1 期
Prophylaxis of venous thromboembolic disease with LMWH (TINzaparin) in patients with metastatic colorectal cancer who start the first line of treatment. - GIT-PRo-2022-02
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 631
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. Male or female subjects with age = 18 years. 2. Written informed consent. 3. Patients with a histologically confirmed diagnosis of stage IV colon or rectal adenocarcinoma (mCRC). 4. Locally assessed BRAF and RAS genomic alterations available during screening. 5. Beginning of the first line of treatment for metastatic disease with chemotherapy +/- targeted therapy (i.e. antiangiogenic, anti-EGFR, encorafenib-cetuximab doublet) or immunotherapy. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 7. Life expectancy >6 months.
排除标准
- •1. Contraindication to tinzaparin, or other heparins: a. Allergy (or hypersensitivity) to heparin, tinzaparin, other LMWHs, or pork products. b. History or presence of heparin-induced (type II) thrombocytopenia. c. Have or have had an epidural catheter or a traumatic spinal puncture within the previous 7 days. 2. Prothrombin time (PT) (International normalized ratio [INR] >1.5 for any reason) or aPTT >2 times control value. 3. Active or recent (<3 months) major bleeding or conditions predisposing to major bleeding. A major bleeding is defined as one that meets one of the following three criteria: a. occurring in a critical area or organ (for example, intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular or pericardial, intrauterine or intramuscular with compartment syndrome), b. causing a decrease in hemoglobin levels of 2 g/l (1.24 mmol/l) or more, or c. that requires a transfusion of two or more units of whole blood or packed red blood cells. 4. Lesions or conditions at increased risk of clinically significant bleeding, including: a. Previously diagnosed/treated VTE = 28 days prior to randomization. b. Active ulcer disease. c. Diagnosed cerebral metastases. d. Stroke within the prior 6 months. e. History of central nervous system (CNS) or intraocular bleeding. 5. Requirement of other anticoagulant therapy, dual antiplatelet therapy, daily non-steroidal anti-inflammatory drugs, or other medications known to increase the risk of bleeding. Note: A daily dose of =100 mg of aspirin and single agent clopidogrel are permitted 6. Acute or chronic renal insufficiency with Creatinine clearance < 30 ml / min. 7. Platelet count < 80.000 /µl at the time of inclusion. 8. Severe liver insufficiency as defined by clinical manifestations of ascites, cirrhosis, encephalopathy and/or jaundice and/or biochemical abnormalities in liver function tests including: a. elevated levels of total bilirubin (> 2 times the upper limit normal [ULN]), b. elevated liver transaminases ALT or AST (> 2 times the ULN; > 5 in case of hepatic metastasis). 9. Participating in another study of an investigational agent at the time of enrollment. Note: Use of an experimental regimen of an approved product is not cause for exclusion. 10. Patients who weigh < 50 Kg. 11. Women of childbearing potential (WOCBP), must provide a negative serum or urine pregnancy test at screening. Women breastfeeding are not eligible. Note: A pregnancy test is performed on WOCBP as per standard of care for patients undergoing anticancer treatments. 12. Any underlying medical or psychiatric disorder, which, in the opinion of the investigator, makes the administration of tinzaparin unsafe or interferes with the informed consent process or trial procedures.
研究者
相似试验
尚未招募
4 期
Prophylaxis of venous thromboembolism in patients with a fracture of the lower extremity being treated conservatively with a below-knee plaster cast.thrombosis10014523pulmonary embolismNL-OMON39940Vrije Universiteit Medisch Centrum670
进行中（未招募）
1 期
The SYMPTOMS (SYstematic elderly Medical Patients Thromboprophylaxis : efficacy on symptomatic OutcoMeS) studyMedDRA version: 18.0Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisSystem Organ Class: 100000004865Venous ThromboembolismEUCTR2014-000311-13-FRCHRU de Brest5,030
已完成
不适用
Prevention of venous thromboembolism using thromboprophylactic- transcutaneous electrical nerve stimulatioPatients who undergo total knee arthroplastyJPRN-UMIN000006932Department of Orthopaedic Surgery, Kochi Medical School, Kochi University86
招募中
不适用
The prevention of venous thromboembolization following by using elastic bandageVenous thromboembolizationJPRN-UMIN000043886iigata University Graduate School300
进行中（未招募）
不适用
Prevention of venous thromboembolism in patients with intracranial hemorrhageSpontaneous intracranial hemorrhageMedDRA version: 14.1Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-002992-40-ITIVERSITA' DEGLI STUDI DI PERUGIA